tbuckley/cabot-search huggingface dataset:
Hormone-Conditional Activation of Bcr-Abl Kinase Highlights Stat5 Anti-Apoptotic Pathway Prior to Promoting Cell Growth.
Authors: Ratanakanit Harnprasopwat, Naoyuki Takahashi, Seiichiro Kobayashi, Kazuaki Yokoyama, Kiyoko Izawa, Ai Kotani, Toshio Kitamura, Arinobu Tojo
Journal: Blood (2010)
GFI1b As a Novel Oncosuppressor in AML
Authors: Aniththa Thivakaran, Lacramioara Botezatu, Judith Maria Hoenes, Yahya Saleh Al-Matary, Nadine Olberding, Judith Schütte, Renata Köster, Bertram Opalka, Ulrich Dührsen, Cyrus Khandanpour
Journal: Blood (2016)
Finding the Best Therapy for Elderly Frail AML Patients: A Retrospective Comparison of 5-Azacytidine and Intensive Approach
Authors: Giordana Pastori, Fabio Guolo, Paola Minetto, Marino Clavio, Enrico Balleari, Nicoletta Colombo, Giulia Rivoli, Lisette Del Corso, Filippo Ballerini, Livia Giannoni, Laura Mitscheunig, Clara Dellepiane, Daniela Guardo, Maurizio Miglino, Roberto Massimo Lemoli, Marco Gobbi
Journal: Blood (2016)
Mechanisms of Clonal Evolution of Pre-Leukemic Clones in Childhood Pre-B Acute Lymphoblastic Leukemia
Authors: Srividya Swaminathan, Lars Klemm, Eugene Park, Anthony M Ford, Soo-mi Kweon, Daniel Trageser, Brian Hasselfeld, Nadine Henke, Huimin Geng, Klaus Schwarz, Rafael Casellas, David G. Schatz, Michael R Lieber, Elli Papaemmanuil, Mel Greaves, Markus Muschen
Journal: Blood (2014)
Induction Of p53 Transcription and Apoptosis By XPO1 Inhibition In Mantle Cell Lymphoma
Authors: Mariko Yoshimura, Jo Ishizawa, Archana Dilip, Sharon Shacham, Michael Kauffman, Yoko Tabe, Shinya Kimura, Michael Andreeff, Kensuke Kojima
Journal: Blood (2013)
Transplant Outcomes in High-Risk (Class 3) Patients with Thalassemia Treated with a Modified Protocol Are Equivalent to Low/Intermediate-Risk (Class 1/Class 2) Patients
Authors: Javid Gaziev, Gioia De Angelis, Antonella Isgro, Pietro Sodani, Marco Marziali, Katia Paciaroni, Marco Andreani, Manuela Testi, Cristiano Gallucci, Cecilia Alfieri, Michela Ribersani, Maria Troiano, Aldo Morrone, Guido Lucarelli
Journal: Blood (2015)
Advanced molecular characterization using Digital Spatial Profiling Technology on immuno-oncology targets in methylated compared with unmethylated IDH-wildtype glioblastoma
Authors: Hannah Barber, Beatrice Lander, Aled Daniels, Antonis Tofias, Jing Jing Gong, Yuqi Ren, Xing Ren, Yan Liang, Paul White, Kathreena M Kurian
Journal: Neuro-Oncology (2019)

Abstract Introduction Glioblastoma (GBM) is the most common primary adult brain tumour with 12–15 months median overall survival. Molecular characterization of multiple immuno-onology targets in GBM is required to optimise immunotherapeutic strategies. Advanced molecular characterisation using Digital Spatial Profiling Technology allows assessment of multiple immuno-oncology protein targets in methylated compared with unmethylated Glioblastoma IDH-wildtype. Methods Nanostring DSP uses multiple primary antibodies conjugated to indexing DNA oligos with a UV photocleavable linker. Tissue Regions of interest (ROI) are selected with bound fluorescent antibodies, oligos are released via a UV-mediated linker and quantitated. We used DSP multiplex analysis of 31 immuno-oncology proteins and controls (PD-1, PD-L1, B7-H3, VISTA, CD45, CD45RO, CD3, MS4A1 (CD20), CD4, CD8A, CD68, STAT3, STAT3 (Phopshory705), GZMB, Beta-2-microglobulin, CD56, Beta-catenin, FOXP3, CD14, CD19, AKT, P-AKT, PTEN, Bcl-2, CD44, Histone H3, S6, IgG Rabbit Control, Mouse IgG Control, Pan-Cytokeratin, Ki67) from ROIs in a cohort of 10 Glioblastomas IDH-wildtype (5 methylated, 5 unmethylated). An nCounter platform allowed quantitative comparisons of antibodies between ROIs in MGMT methylated and unmethylated tumours. Mean protein expression counts between methylated and unmethylated GBM were compared using a linear mixed effect model for technical and biological replicates. Results GeoMx DSP showed 10/27 immuno-oncology target proteins were significantly increased in methylated versus unmethylated Glioblastoma IDH-wildtype (false discovery rate FDR &lt;0.1 by Benjamini-Hocheberg Procedure). Conclusions Increased immuno-oncology protein target expression in methylated versus unmethylated glioblastoma IDH-wildtype using DSP platform has been identified. Advanced multiplex immuno-oncological biomarker analysis is required to identify predictive biomarkers for novel immunotherapeutic agents in GBMs.
GSK recalls ranitidine products over potential carcinogen contamination
Authors: Elisabeth Mahase
Journal: BMJ (2019)

Pharmacies should stop dispensing four prescription ranitidine products supplied by GlaxoSmithKline (GSK) and should return any stock to the company, says an alert issued by the UK Medicines and Healthcare Products Regulatory Agency (MHRA).1

The alert said that the recall was a “precautionary measure” owing to the products potentially being contaminated with an impurity, N -nitrosodimethylamine (NDMA), which has been identified as a potential carcinogen.

But it also told doctors to advise patients not to stop taking their …
Do FISH Lesions Have Any Role in the Pathogenesis and Outcome of Chromosomally Normal MDS?
Authors: Paolo Bernasconi, Irene Dambruoso, Marina Boni, Paola Maria Cavigliano, Ilaria Giardini, Barbara Rocca, Rita Zappatore, Celeste Calvello, Marilena Caresana
Journal: Blood (2011)
Microenvironment-Mediated Regulation of Micrornas In B-Lymphocytes as a Novel Mechanism for Terminal B-Cell Differentiation and Lymphomagenesis.
Authors: Jianhong Lin, Tint Lwin, Wayne Tam, Jian-Jun Zhao, Luis Crespo, Yong Sung Choi, Xinwei Zhang, Victoria Tannenbaum, Eduardo M. Sotomayor, Lynn C. Moscinski, William S. Dalton, Ken Wright, Jianguo Tao
Journal: Blood (2010)
Randomized Clinical Trial of Rasburicase Administered as a Standard Fixed Five Days Dosing Vs a Single Dose Followed by as Needed Dosing in Adult Patients with Hematologic Malignancies at Risk for Developing Tumor Lysis Syndrome.
Authors: Saroj Vadhan-Raj, Luis Fayad, Michelle Fanale, Barbara Pro, Alma Rodriguez, Frederick Hagemeister, Kandice Ames, Carlos E. Bueso-Ramos, Xiao Zhou, Peter McLaughlin, Nathan Fowler, Jatin Shah, Felipe Samaniego, Anas Younes, Larry Kwak, Jorge Romaguera
Journal: Blood (2009)
Preservation of Gene Edited Hematopoietic Stem Cells By Transient Overexpression of BCL-2 mRNA
Authors: Carmen Flores Bjurström, Michelle Mojadidi, Anastasia Lomova, Stephen Lai, Sorel Fitz-Gibbon, Matteo Pellegrini, Aaron R Cooper, Georgia R Lill, Michael Kaufman, Gregory J Cost, Michael C. Holmes, Roger P Hollis, Donald B Kohn
Journal: Blood (2016)
Lymphocyte Cytosolic Protein 1 (LCP1) Is a Membrane Associated Molecular Target in Chronic Lymphocytic Leukemia and Is Activated in Microenvironment Signaling
Authors: Danielle L Chappell, Jason A Dubovsky, Leslie A Andritsos, Joseph M. Flynn, Jeffrey A. Jones, John C. Byrd, Natarajan Muthusamy
Journal: Blood (2012)
Profiling of Circulating Exosomes in Patients with Waldenström Macroglobulinemia
Authors: Juliette Marie Charlotte Bouyssou, Yosra Aljawai, Amir Yosef, Salomon Manier, Ragyie Rawal, Katsutoshi Kokubun, Adriana Perilla Glen, Antonio Sacco, Jorge J. Castillo, Steven P Treon, Aldo M. Roccaro, Marzia Capelletti, Olivier Hermine, Irene M. Ghobrial
Journal: Blood (2016)
Randomized phase II trial of CBDCA+nab-PTX vs CDDP+GEM in patients with chemo-naïve squamous cell lung cancer: NJLCG1302
Authors: Yuka Fujita, Yosuke Kawashima, Toshiyuki Harada, Taku Nakagawa, Kana Watanabe, Naoto Morikawa, Kei Takamura, Kenya Kanazawa, Tomoya Kuda, Kazuhiro Usui, Akimasa Sekine, Akira Inoue, Shunichi Sugawara
Journal: Annals of Oncology (2019)
Inflammation Induced Expression of Ybx1 Mediates Resistance to JAK-Kinase Inhibitor Therapy in Myeloproliferative Neoplasia
Authors: Carolin Herzog, Anja Polanetzki, Stephanie Frey, Tina M Schnoeder, Denise Wolleschak, Nomusa Mashamba, Veera Raghavan Thangapandi, Kathleen Jentsch-Ullrich, Christoph Kahl, Nicolas Schroeder, Peter R Mertens, Thomas Fischer, Florian H Heidel
Journal: Blood (2014)
Expression of 67-Kda Laminin Receptor (67LR) Relates to the Aggressiveness and Poor Prognosis of AML: Modulation of the Expression of GM-CSF Receptor by 67LR.
Authors: Koji Ando, Yasushi Miyazaki, Daisuke Imanishi, Masako Iwanaga, Hideki Tsushima, Jun Taguchi, Takuya Fukushima, Shinichiro Yoshida, Tomoko Hata, Masao Tomonaga
Journal: Blood (2008)
Late Effects Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) From Alternative Donors In Patients With Fanconi Anemia (FA)
Authors: Praveen Anur, Danielle Friedman, Charles A. Sklar, Kevin C. Oeffinger, Susan E. Prockop, Nancy A. Kernan, Andromachi Scaradavou, Richard J. O'Reilly, Farid Boulad
Journal: Blood (2013)
You Will Never Walk Alone: Codispersal of JC Polyomavirus with Human Populations
Authors: Diego Forni, Rachele Cagliani, Mario Clerici, Uberto Pozzoli, Manuela Sironi
Journal: Molecular Biology and Evolution (2019)

JC polyomavirus (JCPyV) is one of the most prevalent human viruses. Findings based on the geographic distribution of viral subtypes suggested that JCPyV codiverged with human populations. This view was however challenged by data reporting a much more recent origin and expansion of JCPyV. We collected information on ∼1,100 worldwide strains and we show that their geographic distribution roughly corresponds to major human migratory routes. Bayesian phylogeographic analysis inferred a Subsaharan origin for JCPyV, although with low posterior probability. High confidence inference at internal nodes provided strong support for a long-standing association between the virus and human populations. In line with these data, pairwise FST values for JCPyV and human mtDNA sampled from the same areas showed a positive and significant correlation. Likewise, very strong relationships were found when node ages in the JCPyV phylogeny were correlated with human population genetic distances (nuclear-marker based FST). Reconciliation analysis detected a significant cophylogenetic signal for the human population and JCPyV trees. Notably, JCPyV also traced some relatively recent migration events such as the expansion of people from the Philippines/Taiwan area into Remote Oceania, the gene flow between North-Eastern Siberian and Ainus, and the Koryak contribution to Circum-Arctic Americans. Finally, different molecular dating approaches dated the origin of JCPyV in a time frame that precedes human out-of-Africa migration. Thus, JCPyV infected early human populations and accompanied our species during worldwide dispersal. JCPyV typing can provide reliable geographic information and the virus most likely adapted to the genetic background of human populations.
Different Panel of Gene Variants Influence Outcome of Transplant From Sibling Donors Compared to HLA-Identical Unrelated Donors
Authors: Ahmet H Elmaagacli, Michael Koldehoff, Nina Kristin Steckel, Markus Ditschkowski, Rudolf Trenschel, Hellmut Ottinger, Dietrich W. Beelen
Journal: Blood (2012)
A Phase 3 Prospective Randomized International Study (MMY-3021) Comparing Subcutaneous and Intravenous Administration of Bortezomib In Patients with Relapsed Multiple Myeloma
Authors: Philippe Moreau, Halyna V Pylypenko, Sebastian Grosicki, Evgeniy E Karamanesht, Xavier Leleu, Maria E Grishunina, Grigoriy B Rekhtman, Zvenyslava Masliak, Tadeusz Robak, Anna V Shubina, Jean-Paul Fermand, Martin Kropff, James Cavet, Sudha Parasuraman, Huaibao Feng, Donna M Skee, Helgi van de Velde, William M Deraedt, Jean-Luc Harousseau
Journal: Blood (2010)
An assessment of the impact of geographic variation on resection rates and survival for early-stage pancreatic adenocarcinoma.
Authors: Bradley D. McDowell, Brian J. Smith, Anna M Button, James R. Howe, Elizabeth A. Chrischilles, James J. Mezhir
Journal: Journal of Clinical Oncology (2013)

e15052 Background: Pancreatic resection is the only known curative option for pancreatic adenocarcinoma. Resection has been previously reported to be underutilized in patients with early stage disease. To develop a better understanding of this issue and control for treatment selection factors, we examined the relationship between geographic area resection rates and survival in patients with stage I/II pancreatic cancer. Methods: We queried Surveillance, Epidemiology, and End Results (SEER) data for patients with stage I/II cancer of the pancreatic head diagnosed from 2004-2009. We excluded patients with less than 3mo survival. Resection rates were calculated within Health Service Areas (HSAs) across all 18 SEER regions. Resection rate was defined as the number of patients who had an operation divided by the total number diagnosed with early stage pancreatic cancer. Multivariate Cox regression was used to estimate the overall survival effect of HSA rates while controlling for age, gender, marital status, poverty level, education, and AJCC stage. Results: 8,323 patients with stage I (n=1,454) and stage II (n=6,869) disease were analyzed. Pancreatectomy was performed in 476 patients (32.7%) with stage I disease and 3,846 (56.0%) with stage II disease. HSA resection rates were arranged into five groups (quintiles) which ranged from 42.7 to 65.7% (Table). Across the quintiles, median overall survival increased from 11 to 14 months, suggesting a positive association with resection rate. Multivariate analysis revealed that for every 10.00% increase in resection rate, the risk of overall death decreased by 5.26% (p&lt;0.001). Conclusions: Patients with early stage pancreatic cancer who live in areas with higher resection rates have longer average survival times. Because geography should not influence treatment response, we conclude that efforts to raise resection rates should increase survival times in patients for whom there is uncertainty about the risk/benefits of resection. [Table: see text]
Minimal Residual Disease–Directed Therapy for Childhood Acute Myeloid Leukemia: Results of the AML02 Multicenter Trial.
Authors: Jeffrey Rubnitz, Hiroto Inaba, Gary Dahl, W. Paul Bowman, Jeffrey Taub, Ching-Hon Pui, Stanley Pounds, Norman J. Lacayo, Xueyuan Cao, Raul C. Ribeiro, Soheil Meshinchi, Barbara Degar, Gladstone Airewele, Mihaela Onciu, Elaine Coustan-Smith, Dario Campana
Journal: Blood (2009)
Carbapenem-Resistant Enterobacteriaceae (CRE) and Their Impact on Stem Cell Transplantation: A Single Center Experience
Authors: Simona Sica, Sabrina Giammarco, Morena Caira, Teresa Spanu, Livio Pagano, Patrizia Chiusolo, Luca Laurenti, Federica Sorà, Giuseppe Leone, Mario Tumbarello
Journal: Blood (2014)
Phase I Study of Escalating Doses of Lenalidomide Combined with R-CHOP (R2-CHOP) for Front-Line Treatment of B-Cell Lymphomas
Authors: Herve Tilly, Franck Morschhauser, Gilles Andre Salles, Rene-Olivier Casasnovas, Serge Bologna, Thierry Jo Molina, Corinne Haioun, Bertrand Coiffier
Journal: Blood (2011)
Revisit the risk factors of recurrence in node involved HER2-positive breast cancer
Authors: Yoriko Hasegawa, Takahiro Kogawa, Mototsugu Shimokawa, Syota Kusuhara, Yumi Fujimoto, Kennichi Harano, Nobuaki Mastubara, Yoichi Naito, Ako Hosono, Hirofumi Mukai, Toru Mukohara
Journal: Annals of Oncology (2019)
Fas or Fas Ligand Expression Can Determine the Clinical Outcome of Germinal Center Type in Diffuse Large B Cell Lymphoma.
Authors: Yasushi Kojima, Hisashi Tsurumi, Naoe Goto, Michio Sawada, Toshiki Yamada, Takeshi Hara, Takeshi Takahashi, Tetsuya Yamada, Masanao Saio, Eiichi Tomita, Tsuyoshi Takami, Hisataka Moriwaki
Journal: Blood (2004)
Upfront Consolidation Combining Yttrium-90 Ibritumomab Tiuxetan and High Dose Therapy with Stem-Cell Transplantation in Poor Risk Patients with Diffuse Large B-Cell Lymphoma
Authors: Christophe Fruchart, Josette Briere, Renaud Ciappuccini, Olivier Casasnovas, Herve Tilly, Franck Morschhauser, Catherine Sebban, Gilles Salles, Christophe Ferme, Achiel Van Hoof, Dominique Bordessoule, Reda Bouabdallah, Alain Delmer, Christian Gisselbrecht
Journal: Blood (2012)
Stable Blood Group Chimerism in Recipients of ABO Incompatible Allogeneic Stem Cell Transplantation
Authors: Ami Glik, Lilach Bonstein, Nardeen Atwah, Eti Ganon-Elazar, Israel Henig, Nuhad Haddad, Riva Fineman, Jacob M. Rowe, Tsila Zuckerman
Journal: Blood (2014)
Iron Metabolism before Allo-HSCT in Patients with Acute Leukemia and Impact of Iron Overload on Transplantation
Authors: Jimin Shi, Xuying Pei, Yi Luo, Yamin Tan, Yanmin Zhao, Jingsong He, Weiyan Zheng, Xiaoyu Lai, Gaofeng Zheng, Jie Zhang, Maofang Lin, Zhen Cai, He Huang
Journal: Blood (2016)
Autotransplants for Multiple Myeloma (MM) – An Update of the Arkansas Experience Since 1989 In Almost 4000 Patients with Special Emphasis on Third and Further Transplants.
Authors: Bijay Nair, Elias J. Anaissie, Sarah Waheed, Yazan Alsayed, Rachael Sexton, Nathan Petty, Frits van Rhee, Antje Hoering, Bart Barlogie
Journal: Blood (2010)
Mutation of Cellular Retinoic Acid-Binding Protein-II (Crabp-II) Does Not Account for Resistance to All-Trans Retinoic Acid (ATRA) in Relapse Acute Promyelocytic Leukemia (APL).
Authors: Binu-John Sankoorikal, Da-Cheng Zhou, Peter H. Wiernik, Robert E. Gallagher
Journal: Blood (2004)
Intensive Versus Double Intensive Therapy in Untreated Multiple Myeloma: Updated Analysis of the Randomized Phase III Study HOVON 24 MM.
Authors: Pieter Sonneveld, Bronno van der Holt, Christine Segeren, Edo Vellenga, Reinier Raymakers, Gregor Verhoef, Ron Schaafsma, Marinus van Oers, Pierre Weijermans, Wim Fibbe, Shulamit Wittebol, Marinus van Marwijk, Douwe Biesma, Joke Baars, Harry Schouten, Petra Westveer, Monique Steijaert, Henk Lokhorst
Journal: Blood (2004)
Enhancing Therapy To Avoid Fetal Blood Sampling (FBS) In Antenatal Management Of Alloimmune Thrombocytopenia (AIT)
Authors: Karen Manotas, Jenny Jin, Cheryl Vinograd, Julia Gabor, Megan Wissert, Richard L. Berkowitz, Janice G McFarland, James B Bussel
Journal: Blood (2013)
Prolonged Follow-up Confirmed a Role for Upfront Tandem Auto-Allo Transplant in Multiple Myeloma Also in the Era of New Drugs
Authors: Luisa Giaccone, Andrea Evangelista, Francesca Patriarca, Roberto Sorasio, Massimo Pini, Fabrizio Carnevale Schianca, Moreno Festuccia, Lucia Brunello, Francesco Zallio, Enrico Maffini, Paola Omedè, Sara Bringhen, Nicola Mordini, Renato Fanin, Massimo Massaia, Antonio Palumbo, Giovannino Ciccone, Mario Boccadoro, Benedetto Bruno
Journal: Blood (2016)
Identification Of MGMT Polymorphisms As Genetic Markers Of Individual Susceptibility To Therapy-Related Myeloid Neoplasms
Authors: Julie Dubois, Gabriel Etienne, Audrey Laroche-Clary, Axelle Lascaux, Audrey Bidet, Eric Lippert, Sofiane Aitouferoukh, Veronique Saada, Jean-Baptiste Micol, Krimo Bouabdallah, Jacques Robert
Journal: Blood (2013)
Calculating the Tumor Nuclei Content for Comprehensive Cancer Panel Testing
Authors: Masashi Mikubo, Katsutoshi Seto, Atsuko Kitamura, Masato Nakaguro, Yukinori Hattori, Nagako Maeda, Tatsuhiko Miyazaki, Kazuko Watanabe, Hideki Murakami, Tetsuya Tsukamoto, Tetsuya Yamada, Shiro Fujita, Katsuhiro Masago, Shakti Ramkissoon, Jeffrey S. Ross, Julia Elvin, Yasushi Yatabe
Journal: Journal of Thoracic Oncology (2019)
Whole Bone Marrow (BM) Immunophenotypic Profiling for the Identification of Newly Diagnosed Symptomatic Multiple Myeloma (MM) Patients with an MGUS-Like Signature Associated with Long-Term Disease Control (LTDC)
Authors: Bruno Paiva, María-Belén Vidriales, Jose J. Perez, María-Angeles Montalbán, Norma Gutierrez, Laura Rosiñol, Joaquín Martínez-López, María-Victoria Mateos, Lourdes Cordon, Albert Oriol, Maria Jose Terol, Maria Asuncion Echeveste, Raquel Paz, Felipe de Arriba, Luis Palomera, Javier De La Rubia, Joaquín Díaz-Mediavilla, Anna Sureda, Ana Gorosquieta, Adrian Alegre, Alejandro Martín, Alberto Orfao, Juan-Jose Lahuerta, Joan Blade, Jesus F. San Miguel
Journal: Blood (2012)
Non-Stereotypic Follicular Lymphoma B-Cell Receptors Recognize Vimentin as a Shared Autoantigen
Authors: Soung-Chul Cha, Hong Qin, Shivichakravarthy Kannan, Seema Rawal, Weiguo Wu, Juliana Ong, Jinsong Wei, Benjamin Kwak, Sang Kim, Michael Popescu, Daniel Paick, Richard Davis, Larry Kwak, Sattva S. Neelapu
Journal: Blood (2010)
Set7 Is Highly Expressed in B-Lineage Acute Lymphoblastic Leukemia Cells and Overexpression of Set7 Exhibits Antileukemia Effect
Authors: Xiao-Tong Ma, Ya-Kun Mou, Yang-Yang Zhao, Nan Wang, Xiao-Yan Liu, Jing Yin, Yan-Ping Ma, Dan Guo
Journal: Blood (2016)
Survival and Seizure Control have improved for Adult Low-Grade Gliomas over the last eleven years
Authors: Matt Solomons, Rimona Weil, Zane Jaunmuktan, Tedani El-Hassan, Sebastian Brandner, Jeremy Rees
Journal: Neuro-Oncology (2019)

Abstract Background There has been a trend towards earlier and more aggressive resection for adult Low-Grade Gliomas (LGG) in the last decade. This study set out to compare seizure control and survival of unselected adults with LGG seen in the same neuro-oncology clinic over 11 years and to determine if a change in surgical philosophy has led to a corresponding improvement in outcomes. Methods Retrospective analysis using case-note review of 153 adults with histologically verified or radiologically suspected LGG, collecting data on patient, tumour and seizure characteristics in 2006 and 2017. Results We studied 79 patients in 2006 and 74 patients in 2017. There were no significant differences between the two groups in age at presentation, tumour location or histological or molecular subtype. The numbers of complete or partial resections increased from 21.5 % in 2006 to 60.8% in 2017 (p&lt;0.05). There was a highly significant improvement in 5- and 10-year survival from 81.8% and 51.7% in 2006 to 100% and 95.8% in 2017 (p&lt;0.001); and a similar improvement was seen in progression free survival. The proportion of patients with intractable epilepsy reduced from 72.2% in 2006 to 43.2% in 2017 (p&lt;0.05). The neurosurgical morbidity rate was identical in both groups (11.8% in 2006 vs 11.1% in 2017). Conclusion Increasing use of surgery for LGG over the last eleven years has led to substantial improvements in survival and seizure control but not at the cost of long-term morbidity.
Phase 3 Study Of Pomalidomide In Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis With RBC-Transfusion-Dependence
Authors: Ayalew Tefferi, Francesco Passamonti, Tiziano Barbui, Giovanni Barosi, Kebede Begna, Mario Cazzola, Francisco Cervantes, Konstanze Döhner, Heinz Gisslinger, Vikas Gupta, Wang Li, C N Harrison, Jean-Jacques Kiladjian, Mary Frances McMullin, Alessandro Rambaldi, Gary J. Schiller, Alessandro M Vannucchi, Ruben A. Mesa
Journal: Blood (2013)
Re-administration of EGFR-TKI to mutated EGFR NSCLC patients after remission of osimertinib induced ILD
Authors: Kenichi Chikamori, Tadashi Maeda, Kenji Sakamoto, Keisuke Aoe, Toshiaki Utsunomiya, Yoriyuki Murata, Masamoto Nakanishi, Haruhito Kamei
Journal: Annals of Oncology (2019)